BioSig Technologies increases patient case goal to 1,500 procedures by end of 2021

BioSig Technologies increases patient case goal to 1,500 procedures by end of 2021

Proactive Investors

Published

BioSig Technologies Inc (NASDAQ:BSGM), which is commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, has increased its patient case goal to at least 1,500 procedures by the end of 2021. BioSig’s non-invasive computerized technology, the PURE EP System, aims to drive procedural efficiency and efficacy in electrophysiology. The system provides essential diagnostic signals with high clinical value in all cardiac ablations that treat irregular heartbeats or arrhythmias. Previously, the company had announced its target to complete 1,000 patient cases in 2021, having delivered 425 procedures by the end of 2020.  READ: BioSig taps two regional directors to lead its commercial expansion across southeast and central regions of the US The company said it is currently conducting patient cases in nine medical centers across the country. Texas Cardiac Arrhythmia Institute at St. David’s Medical Center in Austin, Texas, its first commercial customer, continues to be the biggest user of the technology with over 300 patient cases conducted to date.  Mayo Clinic Florida Campus and the University of Pennsylvania are the second and third largest patient case drivers with 130 and 112 cases, respectively. And more than 800 procedures have been conducted with the PURE EP System in the last 18 months, “Patient case volume is one of the leading indications of physician utilization of our technology,” said BioSig CEO Kenneth Londoner in a statement. “We see steady procedural growth in almost all of our centers, which we believe will turn into commercial revenues. This case growth, combined with the consistently positive customer feedback, positions us well to deliver on our target of 20 installation sites by the end of 2021.” BioSig noted that one in 18 Americans suffers from cardiac arrhythmia. Atrial fibrillation is the most common arrhythmia type, affecting over 33 million people worldwide, including over 6 million in the US. According to the Centers for Disease Control and Prevention (CDC), atrial fibrillation causes more than 750,000 hospitalizations in the US each year, resulting in about $6 billion in healthcare spending annually. Contact the author: patrick@proactiveinvestors.com Follow him on Twitter @PatrickMGraham

Full Article